A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19.
A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19.
复制标题
DOI：
10.1038/s41598-021-88130-w
复制
发表时间：
2021-04-20
影响因子：
4.6
通讯作者：
Dwivedi AK
中科院分区：
文献类型：
--
作者：
Thakur B;Dubey P;Benitez J;Torres JP;Reddy S;Shokar N;Aung K;Mukherjee D;Dwivedi AK
多种合并症已被证明与 2019 年冠状病毒病 (COVID-19) 的严重程度和死亡率有关。然而，在先前的研究中观察到合并症的患病率估计及其对 COVID-19 发病率和死亡率的影响存在很大差异。这项系统评价和荟萃分析旨在确定 COVID-19 患者中合并症患病率以及相关严重程度和死亡率的地理、年龄和性别相关差异。我们使用 PubMed、Scopus 和 EMBASE 进行了一项搜索，纳入了 2020 年 1 月 1 日至 2020 年 7 月 24 日期间发表的所有报告合并症严重程度或死亡率的 COVID-19 研究。我们纳入了报告人类患者确诊为 COVID-19 的研究，这些研究还提供了有关合并症或疾病结果的信息。我们使用 DerSimonian 和 Laird 随机效应方法来计算估计值。在涉及 125,446 名患者的 120 项研究中，最常见的合并症是高血压（32%）、肥胖（25%）、糖尿病（18%）和心血管疾病（16%），而慢性肾脏或其他肾脏疾病（51%、44%）、脑血管意外（43%、44%）和心血管疾病（44%、40%）患者的 COVID-19 严重程度和死亡率分别更高。观察到不同地理区域合并症的患病率以及相关疾病的严重程度和死亡率存在相当大的差异。在针对患有任何疾病的拉丁美洲和欧洲患者的研究中观察到死亡率最高，其中大多数是老年人（≥65 岁），并且主要是男性患者。尽管美国的研究观察到 COVID-19 患者的合并症患病率最高，但亚洲研究中每种合并症的 COVID-19 严重程度最高，而欧洲和拉丁美洲国家的死亡率最高。应根据特定地理位置的合并症、年龄和性别差异，对 COVID-19 进行风险分层和有效控制策略。
Several comorbidities have been shown to be associated with coronavirus disease 2019 (COVID-19) related severity and mortality. However, considerable variation in the prevalence estimates of comorbidities and their effects on COVID-19 morbidity and mortality have been observed in prior studies. This systematic review and meta-analysis aimed to determine geographical, age, and gender related differences in the prevalence of comorbidities and associated severity and mortality rates among COVID-19 patients. We conducted a search using PubMed, Scopus, and EMBASE to include all COVID-19 studies published between January 1st, 2020 to July 24th, 2020 reporting comorbidities with severity or mortality. We included studies reporting the confirmed diagnosis of COVID-19 on human patients that also provided information on comorbidities or disease outcomes. We used DerSimonian and Laird random effects method for calculating estimates. Of 120 studies with 125,446 patients, the most prevalent comorbidity was hypertension (32%), obesity (25%), diabetes (18%), and cardiovascular disease (16%) while chronic kidney or other renal diseases (51%, 44%), cerebrovascular accident (43%, 44%), and cardiovascular disease (44%, 40%) patients had more COVID-19 severity and mortality respectively. Considerable variation in the prevalence of comorbidities and associated disease severity and mortality in different geographic regions was observed. The highest mortality was observed in studies with Latin American and European patients with any medical condition, mostly older adults (≥ 65 years), and predominantly male patients. Although the US studies observed the highest prevalence of comorbidities in COVID-19 patients, the severity of COVID-19 among each comorbid condition was highest in Asian studies whereas the mortality was highest in the European and Latin American countries. Risk stratification and effective control strategies for the COVID-19 should be done according to comorbidities, age, and gender differences specific to geographical location.
登录
查看更多内容
DOI：
10.1590/s0036-36342012000200014
发表时间：
2012-04-01
期刊：
Salud Pública de México
影响因子：
--
作者：
Fortis, Ángeles;García-Macedo, Rebeca;Cruz, Miguel
通讯作者：
Cruz, Miguel
影响因子：
3.7
作者：
Limsreng, Setha;Marcy, Olivier;Segeral, Olivier
通讯作者：
Segeral, Olivier
DOI：
10.1016/0197-2456(86)90046-2
发表时间：
1986-09-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
DERSIMONIAN, R;LAIRD, N
通讯作者：
LAIRD, N
影响因子：
3.7
作者：
Guan WZ;Qiu GF;Feng-Liu
通讯作者：
Feng-Liu
影响因子：
3.9
作者：
Barbu MG;Thompson RJ;Thompson DC;Cretoiu D;Suciu N
通讯作者：
Suciu N